FROM Fondazione per la Ricerca Ospedale di Bergamo retweetledi

CONGRESS | #ASH2025 | POSTER
Tiziano Barbui shares real-world findings from a cohort of a prospective, non-interventional, post-authorization study (ROPEG-PV), evaluating ropeginterferon alfa-2b (Ropeg) in patients with polycythemia vera (N = 316).
Hematologic response rates improved from 17.9% at baseline to 50.0% at 24 months, with phlebotomy need also declining. Thrombotic events (n=7), disease progression (n=9), secondary cancer (n=3), and deaths (n=3) were infrequent. A total of 88 AEs were reported, including 12 Grade 3–5 events, with SAEs uncommon. Treatment discontinuation reached 20.9% and 31.8% at 12 months and 24 months, respectively.
Follow our live feed for more updates: loom.ly/bBHVibw
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#MPN #MPNsm #PolycythemiaVera #MedEd #MedicalCongress @FromBergamo




English





























